18 May 2013
Keywords: Pfizer, Tofacitinib, Ph III, Rheumatoid arthritis, USA, FDA
Article | 01 August 2012
Pfizer (NYSE:PFE), the world’s largest drugmaker by sales, yesterday released positive top-line results from ORAL Start ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
1 August 2012
17 May 2013
© 2013 thepharmaletter.com